Triphase in-licenses clinically enabled oncology assets with high-value potential and develops them in a shared risk model to proof of concept (POC), then out-licenses or sells the product to realize value. Triphase has formed a strategic partnership with Celgene Corporation to enable the rapid development of proof of concept in important new cancer therapeutics of mutual interest. The Triphase management team is deeply knowledgeable with significant experience in drug development. Together with the founding organizations Ontario Institute for Cancer Research (OICR) and MaRS Innovation, and supported by MaRS Discovery District along with strategic oncology partnerships, Triphase has formed a unique partnership to produce proof-of-concept data for investors, partners, regulators, payers, and ultimately prescribers and patients. MISSION STATEMENT Our Mission is to accelerate the development of promising cancer therapies from pre-IND to proof of concept (Phase II) in order to bring more effective, affordable treatments to cancer patients, faster than traditional drug development. BUSINESS MODEL Triphase focuses on accelerating oncology products from pre-investigational new drug (pre-IND) to Phase I/Phase II POC in less time with less capital than traditional pharma and biotech approaches. It accomplishes this through support from world-class scientists, clinicians, and business professionals, state-of-the-art facilities and entrepreneurial resources predominantly in Canada and the United States. Triphase draws on the people, skills and infrastructure represented in the Toronto / Ontario and San Diego / Southern California bio hubs, and taps into expertise around the world. INTERESTED IN PARTNERING WITH US? If you are interested in collaborating with Triphase Accelerator to develop early compounds to proof-of-concept, email us at info@triphaseco.com.